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RESULTS: Non-compliance is a significant problem in
managing hypercholesterolaemia. Discontinuation rates
for statins in normal practice average 30% after six
months. This results in a significant loss of therapeutic re-
sponse. In the EXCEL study (lovastatin), a 41.3% reduc-
tion in LDL cholesterol was observed in those patients
who reported taking all their tablets. This compared with
a 26.6% reduction in those taking 80% of their tablets. In
a primary-care setting, the discontinuation rate for prava-
statin was 24% after two years. The reduction in LDL
cholesterol was 6% compared to 26% in those continuing
treatment. This results in a change in cost-effectiveness
from £376 to £1754 per % LDL reduction per year.
CONCLUSIONS: Noncompliance is an important factor
when assessing a drug’s effectiveness in clinical practice.
Tables comparing the cost-effectiveness of statins are of-
ten found in the medical literature, but rarely do they ac-
count for noncompliance. The present study illustrates
the need to account for the impact of noncompliance in
pharmacoeconomic evaluations.
PCV6
AVAPROMISE: A RANDOMIZED CLINICAL TRIAL 
FOR INCREASING COMPLIANCE THROUGH 
BEHAVIORAL MODIFICATION IN 
ESSENTIAL HYPERTENSION
Hamet P1, Campbell N2, Curnew G3, Eastwood C4, Pradhan A5
1Centre Hospitalier de l’Universite de Montreal, University of 
Montreal, Montreal, QC, Canada; 2Health Sciences Centre, 
University of Calgary, Calgary, AB, Canada; 3Hamilton General 
Hospital, Hamilton, ON, Canada; 4BTB Associates, Ancaster, 
ON, Canada; 5Bristol-Myers Squibb Canada, St. Laurent, QC, 
Canada
OBJECTIVE: Patients with hypertension are often non-
compliant with their medication. A study was conducted
in a usual clinical practice setting in patients with essen-
tial hypertension to improve medication compliance by
modifying behavior.
METHODS: The trial was designed as a randomized,
multi-center, open-label, two-arm study in patients with
essential hypertension. Four thousand eight hundred
sixty four patients recruited from general practice settings
were randomized to receive the angiotensin-receptor
blocker irbesartan with (intervention group) or without
(non-intervention group) a behavioral modification pro-
gram (Avapromise), which was based on a model of
change, and followed up for 12 months. Randomization
to Avapromise was done by site (recruiting physicians’
office) such that all the patients within one site were ran-
domized to the same treatment regimen to avoid contam-
ination and to minimize investigator bias. Patients were
sub-grouped based on their stage of change in the behav-
ioral change continuum, and the intervention was tai-
lored to address the needs of the particular sub-group.
Primary efficacy measure was rate and time to discontin-
uation with irbesartan.
RESULTS: At the end of the study the total number of
patient discontinuations was 1240 (25% of 4864). Of
these, 611 (25.4%, 95% CI: 23.7–27.2) occurred in the
intervention group and 629 (25.5%, 95% CI: 23.8–27.3)
occurred in the non-intervention group. This resulted in a
difference of 0.1% (2.6 to 2.3) between the two groups
(p  0.94). The time to discontinuation was not different
between the groups (p  0.87). The extrapolated rate of
discontinuation estimated from the Kaplan-Meier curve
was also not different between the groups (intervention:
23.1%, 95% CI: 21.3–24.8; non-intervention: 23.5%,
95% CI: 21.8–25.3).
CONCLUSION: This behavioral modification interven-
tion based on a model of change was not effective in in-
creasing compliance rates in patients with essential hy-
pertension in this setting.
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OBJECTIVE: The development of low-molecular-weight
heparins (LMWHs) as an antithrombin therapy for the
management of acute coronary syndromes was prompted
by the shortcomings of unfractionated heparin (UFH), the
standard therapy. LMWHs, and especially the most widely
used enoxaparin, offer the advantages of a stable and pre-
dictable anticoagulant response to a given dose, eliminat-
ing the need for haematologic monitoring, and much sim-
pler administration via the subcutaneous route. However,
enoxaparin should achieve improved clinical effectiveness
and demonstrate economic attractiveness. The present re-
view is an appraisal of the relative costs and benefits of
enoxaparin versus UFH in acute cardiology.
METHODS: A growing number of papers have been ad-
dressing these questions during the last five years. Most
of them are based on two worldwide multi-center, dou-
ble-blind, randomized controlled trials, TIMI 11B and
ESSENCE, involving patients with unstable angina/
non-Q wave myocardial infarction. Efficiency was evalu-
ated prospectively over the first 30 days of follow-up and
retrospectively after one year of follow up, using cost-ef-
fectiveness approach. Only direct costs were measured.
RESULTS: Enoxaparin was shown to be a dominant
strategy. It clearly improved efficacy and tolerability ver-
sus UFH, providing an absolute risk reduction of death,
myocardial infarction and recurrent angina of 3.7% to
3.5% at more or less short term. Average cost per patient
was significantly lower due to reduced frequency of diag-
nostic catheterization, revascularization procedures, an-
giography, coronary angioplasty and shorter length of
hospital stay over the first 30 days. Cost reduction arose,
on the long term, from less rehospitalizations and revas-
cularizations. Moreover, those reductions were probably
underestimated as indirect costs were not considered.
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CONCLUSION: Superior clinical efficacy combined with
substantial cost savings for at least one year of follow up
conferred to enoxaparin a place of choice in acute cardi-
ology therapy.
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OBJECTIVE: To determine the cost-effectiveness of
thrombosis prevention with Clopidogrel versus Ticlopi-
dine in Russia, taking into account side effect such as
agranulocytosis (neutropenia) using a decision analysis.
METHODS: Pharmacoeconomic comparison using a de-
cision-tree model was based on the assumption that
Ticlopidine (250 mg daily) causes short-duration neutro-
penia in 0,8% of patients compared to 0,04% of patients
on Clopidogrel (37,5 mg daily) one month after treat-
ment starts. The probabilities of neutropenia were de-
rived from multi-center clinical trials of antithrombotic
therapy safety. Calculated costs included cost of study
drugs and direct medical costs for neutropenia treatment.
A neutropenia treatment scheme was analyzed by review-
ing medical charts of patients with short-duration neutro-
penia at the Federal Hematological Center. Effectiveness
was measured by percentage reduction in spontaneous
platelet aggregation (SPA) in a comparative clinical study
including 70 patients with thrombophilia. Cost effective-
ness ratio (CER) was defined for both drugs and incre-
mental cost-effectiveness ratio (ICER) was determined.
RESULTS: The mean costs of medication treatment were
1221 rubles (42,1$) for Clopidogrel and 795 rubles
(27,4$) for Ticlopidine. The median direct medical cost
for treatment of neutropenia was 28,126 rubles (969,9$)
per patient. Expected costs for antiplatelet therapy, tak-
ing into account the probability of neutropenia, was
1020 rubles (35,2$) for Ticlopidine and 1232 rubles
(42,5$) for Clopidogrel. The CER for Clopidogrel was
19,4 rubles (0,67$) and 20,6 rub (0,71$) for Ticlopidine
per 1% of SPA reduction. The ICER for Clopidogrel vs.
Ticlopidine was 14,5 rub (0,5$) per 1% SPA reduction.
CONCLUSION: Clopidogrel is more effective and safe
than Ticlopidine. Though costs for Clopidogrel including
treatment of side effects (neutropenia) were higher than
for Ticlopidine, ICER shows that additional effects can
be achieved at a reasonable cost.
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OBJECTIVE: To conduct an economic analysis of the
PURSUIT trial in the UK for patients with unstable an-
gina or non-Q-wave myocardial infarction (MI) admitted
to hospital and randomized to eptifibatide (GPIIb/IIIa) or
placebo in addition to usual therapy.
METHODS: Health-care resource consumption was col-
lected prospectively for all patients in the PURSUIT trial.
Unit costs were developed for the UK and applied to the
resources consumed in the trial to estimate the cost per
patient treated during index hospital stay and at six
months follow-up. Analyses were conducted using resource
consumption from the UK sub population, Western Eu-
ropean (WE) sub population, and the total PURSUIT trial
population. Long term outcome measures were based on
life expectancy estimated from six-month PURSUIT data of
the WE sub-population and the North American (NA) 
WE sub populations.
RESULTS: Initial hospital and six-month costs for eptifi-
batide patients including drug cost were slightly higher
than the placebo group using the WE and overall trial
population resources. UK-specific resource consumption
was lower in the eptifibatide group. The difference in 30-
day rate of death and MI was 1% (NS) for WE and 1.5%
(p  0.04) for the overall trial. At six months, MI rates
were further decreased for eptifibatide but no difference
existed in mortality between the groups. The CE ratios
(discounted at 3%) using WE or overall resources are
£8,436 and £12,591 respectively using WE survival or
£3,418 and £5,036 using WE  NA survival. Using UK
resources, eptifibatide is cost saving in either survival sce-
nario.
CONCLUSION: The cost-effectiveness ratios for eptifi-
batide in the UK all fall within an acceptable range for
adopting new technology. The impact of resource con-
sumption data on the cost-effectiveness ratio underscores
the importance of the source of treatment-pattern data
and the need for prospective or retrospective data collec-
tion to reflect country-management styles.
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OBJECTIVE: The objective of this analysis was to evalu-
ate the health-economic benefits of using amlodipine in
patients undergoing angioplasty procedures from the per-
spectives of the Canadian Ontario Ministry of Health
and the Norwegian National Health Service.
